www.microbioncorp.com

Microbion

Address:

374 – 135o Burrard Street 

Vancouver, BC V6Z 0C2

Canada

Member Sector: Biopharmaceuticals

Microbion, a clinical stage biopharmaceutical company, is developing MBN-101 as the first product in a new class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of Gram-negative and Gram-positive pathogens, including multiple priority pathogens or “superbugs.” In addition to anti-bacterial efficacy, MBN-101 has also demonstrated the ability to eradicate biofilms. This dual antimicrobial action from this first-in-class product provides a novel clinical approach to treating infections. Microbion filed an IND in the United States for MBN-101 in 2015. The company initiated its first Phase 2a study in 2016. MBN-101 has been granted Qualified Infectious Disease Product (QIDP) designation by the FDA for post-surgical orthopedic implant infections and was also granted Fast Track designation for this indication by the FDA in 2015. The company has also been granted QIDP and Fast Track designations by the FDA for adjunctive treatment of moderate and severe diabetic foot infections in 2016. For more information visit www.microbioncorp.com